Physician profile
Ryan Goetz
NPI 1063975530
$4,822.95
in general payments reported to CMS, 2019-2025
22 companies · $4,034 in 2025
The $4,034 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $16.53 · 2022: $178 · 2024: $594 · 2025: $4,034.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $2,500 · Food and Beverage: $1,902 · Travel and Lodging: $226.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $2,500.00 |
| Food and Beverage | $1,901.85 |
| Travel and Lodging | $226.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $2,862.73 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $592.63 | 2021-2025 | Fasenra, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $465.03 | 2022-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Regeneron Healthcare Solutions, INC. | $134.61 | 2025 | Dupixent |
| Genzyme Corporation | $104.04 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $82.45 | 2025 | Cuvitru |
| Merck Sharp & Dohme LLC | $74.18 | 2025 | Winrevair |
| Abbvie INC. | $65.50 | 2022 | |
| Mallinckrodt Hospital Products INC. | $61.46 | 2025 | Acthar |
| La Jolla Pharmaceutical Company | $57.11 | 2024-2025 | Giapreza |
| Shionogi INC | $48.36 | 2022-2025 | Fetroja |
| Amgen INC. | $41.11 | 2025 | Tezspire |
| Viatris Specialty LLC | $39.80 | 2025 | Yupelri |
| Verona Pharma, INC. | $36.24 | 2025 | Ohtuvayre |
| Jazz Pharmaceuticals INC. | $35.89 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $20.39 | 2025 | Prolastin-C Liquid |
| Inspire Medical Systems, INC. | $20.34 | 2025 | Inspire |
| Electromed, INC. | $18.61 | 2025 | Smartvest |
| Pfizer INC. | $17.03 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.02 | 2025 | Jascayd |
| Inogen, INC. | $14.93 | 2025 | |
| Pulmonx Corporation | $14.49 | 2025 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Goetz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.